Physician profile
Garrett Dyer
NPI 1366269508
$429.26
in general payments reported to CMS, 2019-2025
14 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $81.10 | 2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $45.39 | 2025 | |
| Axsome Therapeutics, INC. | $37.26 | 2025 | Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.00 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $31.94 | 2025 | Farxiga |
| Pfizer INC. | $30.31 | 2025 | |
| Almatica Pharma LLC | $29.85 | 2025 | Loreev Xr, Teriparatide |
| Teva Pharmaceuticals USA, INC. | $29.10 | 2025 | Austedo Xr |
| Lilly USA, LLC | $20.01 | 2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $19.96 | 2025 | Rexulti |
| Lundbeck LLC | $19.83 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $17.60 | 2025 | Spravato |
| Glaxosmithkline, LLC. | $17.14 | 2025 | Trelegy Ellipta |
| Globus Medical, INC. | $14.77 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.